Current Status of Financing and Reimbursement of Herceptin® (Trastuzumab) for Adjuvant and Advanced Therapy of Breast Cancer in Germany.

Volker Jacobs

Current Status of Financing and Reimbursement of Herceptin® (Trastuzumab) for Adjuvant and Advanced Therapy of Breast Cancer in Germany.

^*Corresponding author for this work

Research output: Contribution to journal › Original Article › peer-review

Original language	English
Pages (from-to)	86-94
Journal	Breast care (Basel, Switzerland)
Volume	1
Issue number	2
Publication status	Published - 2006

Access to Document

http://www.karger.com/Article/Abstract/92559

Cite this

@article{8c778f30ff534a73a148bc2b9984363a,

title = "Current Status of Financing and Reimbursement of Herceptin{\textregistered} (Trastuzumab) for Adjuvant and Advanced Therapy of Breast Cancer in Germany.",

author = "Volker Jacobs",

year = "2006",

language = "English",

volume = "1",

pages = "86--94",

journal = "Breast care (Basel, Switzerland)",

issn = "1661-3791",

publisher = "Karger ",

number = "2",

}